Personalis Inc (NASDAQ: PSNL) shares have risen 12.69%, or $0.58 per share, as on 12:05:58 est today. Since opening the day at $4.75, 261,418 shares of Personalis have been traded today and the stock has traded between $5.15 and $4.70.  

Already the company has a YTD change of 67.97%.

Personalis is set to release earnings on 2022-08-04.

For technical charts, analysis, and more on Personalis visit the company profile.

About Personalis Inc

Personalis, Inc. is a leader in population sequencing and cancer genomics, with a focus on data, scale, efficiency and quality. Personalis operates one of the largest sequencing operations globally and is currently the sole sequencing provider to the VA MVP. In oncology, Personalis is transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient's cancer and immune response. The Personalis® ImmunoID NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. The PersonalisClinical Laboratory is GxP-aligned as well as CLIA'88-certified and CAP-accredited.

To get more information on Personalis Inc and to follow the company's latest updates, you can visit the company's profile page here: Personalis Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Trending Articles

Big Lots Down 18% in Premarket Trading Friday on Surprise Missed Earnings

Modine Posts Strong Rebound in Fiscal Q4, Raises 2023 Guidance

Dollar Tree Posts Record First Quarter, Leads Nasdaq Gainers

Kohl's Still in Play To Be Acquired

Chinook Therapeutics Raises $105 Million for Kidney Disease Therapies

Market Conditions Driving Higher Base Level for VIX Volatility Index

Will New AT&T, Dish Co-opetition Deal Work: Jeff Kagan

Cisco Down 12% in Premarket Trading Thursday After Top Line Miss and Lower Forecast